Nurix Therapeutics (NRIX) Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Current Assets data on file, last reported at $554.4 million in Q1 2026.

• Current Assets for Q1 2026 came in at $554.4 million, down 1.65% year-over-year; the trailing twelve-month figure through Feb 2026 was $554.4 million (down 1.65% YoY), and the FY2025 annual result was $606.8 million, down 2.03% from the prior year.
• Current Assets slipped to $554.4 million in Q1 2026 per NRIX's latest filing, from $606.8 million in the prior quarter.
• Over five years, Current Assets peaked at $619.4 million in Q4 2024 and troughed at $251.0 million in Q1 2024.
• A 5-year average of $403.5 million and a median of $354.9 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets slipped 24.49% in 2023, then jumped 124.61% in 2025.
• A 5-year view of Current Assets shows it stood at $318.4 million in 2022, then retreated by 7.21% to $295.5 million in 2023, then surged by 109.6% to $619.4 million in 2024, then decreased by 2.03% to $606.8 million in 2025, then retreated by 8.64% to $554.4 million in 2026.
• Business Quant data shows NRIX's Current Assets at $554.4 million in Q1 2026, $606.8 million in Q4 2025, and $440.6 million in Q3 2025.